Systagenix’s WoundChek now used by more than 1,000 trained staff

Systagenix has announced that more than 1,000 clinicians have been trained to use its WoundChek Protease Status testing system since its launch earlier this year.

Medical professionals based at more than 400 sites across Europe, the Middle East and South Africa have been training themselves in the use of the world's first point-of-care test for elevated protease activity (EPA) in chronic wounds.

The EPA testing method – which makes it easier to identify wounds that are proving resistant to healing – has been included in NHS guidelines as part of the assessment to determine care pathways for venous leg ulcers.

Meanwhile, six consensus documents on the importance of testing for EPA have been written in the last 18 months by a total of over 60 wound care experts from around the world.

Paolo Di Vincenzo, Systagenix's vice-president for global marketing, said: "With EPA having such a huge impact on the chances of healing, we are glad to offer a tool that for the first time can help clinicians identify and treat these patients."

This comes after the firm won a prestigious Gatwick Diamond Business Award for WoundChek Protease Status earlier this year.